Industry & Business

OncoMark Secures €2.1 Million Investment to Commercialise Breast Cancer Diagnostic Test

 Breaking News
  • HBAN Scoops Major European Business Angel Network Award HBAN (Halo Business Angel Network), the all-island organisation responsible for the promotion of business angel investment, and a joint initiative of Enterprise Ireland and InterTradeIreland, was crowned Globally Networked Organisation 2018 at the recent EBAN (European Business Angel Network) Awards Ceremony held in Sofia, Bulgaria. HBAN was awarded the prominent European accolade in recognition of the significant [...]...
  • Irish Whiskey Industry Welcomes EU-Japan Trade Agreement The Irish Whiskey Association has welcomed the signing of the EU-Japan Economic Partnership Agreement, the largest trade deal negotiated yet by the European Union. While sales of Irish whiskey remain relatively low, Japan is currently the largest market in Asia for Irish whiskey and last year Irish whiskey sales in Japan recorded a 15.7% growth to [...]...
  • BD Opens New State-of-the-art R&D Facility in Limerick BD, a leading global medical technology company, is to create 85 new jobs for the Limerick region. The announcement was made as Minister for Trade, Employment, Business, EU Digital Single Market and Data Protection Pat Breen TD, officially opened BD’s Research Centre Ireland (RCI) in Limerick’s National Technology Park. The €21 million investment in BD’s [...]...
  • National Project Awards 2018 Open For Entries Entries for the Ireland Chapter of Project Management Institute’s (PMI) National Project Awards, sponsored by PwC, are open. Over 120 applicants entered the awards last year, which celebrate the country’s leading project managers and teams and their forward-thinking projects. This year the Awards recognise the importance of community-led non-profit projects with the introduction of a new [...]...
  • McAleer & Rushe Transforming Edinburgh’s Old Town The new UK Government hub planned for New Waverley in the heart of Edinburgh’s Old Town, which is being constructed by Northern Ireland-based design and build company McAleer & Rushe, has reached a significant milestone with the official ‘Topping Out’ of the office scheme. The project which is transforming a UNESCO Heritage site, in one [...]...

OncoMark Secures €2.1 Million Investment to Commercialise Breast Cancer Diagnostic Test

OncoMark Secures €2.1 Million Investment to Commercialise Breast Cancer Diagnostic Test
February 16
12:36 2017

OncoMark, a University College Dublin (UCD) spin-out company, announced on Wednesday that it has secured €2.1 million to fund the commercialisation of OncoMark’s lead product, OncoMasTR, which it plans to launch in 2018. OncoMasTR is a novel prognostic test for early-stage breast cancer that will reduce the number of breast cancer patients receiving unnecessary chemotherapy.

OncoMark CEO Des O ‘Leary said: In the absence of accurate tests, the majority of early-stage breast cancer patients are treated with chemotherapy despite many not benefiting from the treatment. This exposes individuals to severe side effects and results in significant costs to healthcare systems worldwide. Approximately 70% of patients do not require chemotherapy after initial surgery, but it has been difficult to identify these individuals. The OncoMasTR test is designed to enable a more personalised approach to patient care, helping clinicians to determine which patients should not receive chemotherapy, ultimately improving their quality of life.”

The funding round included; Kernel Capital, through the Bank of Ireland Kernel Capital Venture Funds, the Irrus Investments syndicate, the Galway HBAN MedTech syndicate, private investors and Enterprise Ireland.

OncoMark was previously awarded €2.7 million, through the Horizon 2020 SME Instrument Phase 2, to clinically validate the OncoMasTR test. This new funding round will allow the translation of the test from clinical validation to regulatory approval and full commercialisation.

Dr Tom Kelly, Head of Division, Industrial, Lifesciences and Consumer, Enterprise Ireland said, “The thriving Irish medtech sector continues its story of success and the development of innovative products such as OncoMasTR contributes significantly to Ireland’s reputation as a leading global cluster for medical technologies. Companies like OncoMark are the future of the Irish economy. They have used Ireland’s extensive innovation ecosystem and worked with the Enterprise Ireland commercialisation team to bring the fruits of academic enquiry to market and profitably”.

OncoMark is focused on the development of novel panels of cancer biomarkers, to aid treatment decisions and allow more tailored patient management, ultimately improving the quality of life for cancer patients.

OncoMark, which was co-founded by Professor William Gallagher and Steve Penney as a spin-out from UCD’s School of Biomolecular and Biomedical Science, is headquartered at NovaUCD, the Centre for New Ventures and Entrepreneurs.

The OncoMasTR test is based on a panel of genetic ‘drivers’ of breast cancer. The original research that resulted in the identification of the panel was led by Professor Adrian Bracken, Smurfit Institute of Genetics, Trinity College Dublin and researchers at the UCD Conway Institute, led by Professor William Gallagher. The OncoMasTR technology was subsequently exclusively licenced by both universities to OncoMark.

 

About Author

editor

editor

Related Articles

New Subscriber





Subscribe Here



Advertisements



















National Manufacturing Conference & Exhibition 2018

NIBRT Springboard Success Stories



Upcoming Events

  • No upcoming events
AEC v1.0.4